These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 32720702)

  • 21. Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India.
    Dravid A; Kashiva R; Khan Z; Memon D; Kodre A; Potdar P; Mane M; Borse R; Pawar V; Patil D; Banerjee D; Bhoite K; Pharande R; Kalyani S; Raut P; Bapte M; Mehta A; Reddy MS; Bhayani K; Laxmi SS; Vishnu PD; Srivastava S; Khandelwal S; More S; Shinde R; Pawar M; Harshe A; Kadam S; Mahajan U; Joshi G; Mane D
    Medicine (Baltimore); 2021 Jul; 100(29):e26705. PubMed ID: 34398044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
    Santos CS; Férnandez XC; Moriano Morales C; Álvarez ED; Álvarez Castro C; López Robles A; Pérez Sandoval T
    RMD Open; 2021 Jan; 7(1):. PubMed ID: 33455920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Higher levels of IL-6 early after tocilizumab distinguish survivors from nonsurvivors in COVID-19 pneumonia: A possible indication for deeper targeting of IL-6.
    Quartuccio L; Sonaglia A; Pecori D; Peghin M; Fabris M; Tascini C; De Vita S
    J Med Virol; 2020 Nov; 92(11):2852-2856. PubMed ID: 32515499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.
    Roumier M; Paule R; Vallée A; Rohmer J; Ballester M; Brun AL; Cerf C; Chabi ML; Chinet T; Colombier MA; Farfour E; Fourn E; Géri G; Khau D; Marroun I; Ponsoye M; Roux A; Salvator H; Schoindre Y; Si Larbi AG; Tchérakian C; Vasse M; Verrat A; Zuber B; Couderc LJ; Kahn JE; Groh M; Ackermann F;
    J Clin Immunol; 2021 Feb; 41(2):303-314. PubMed ID: 33188624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deep vein thrombosis and pulmonary embolism among hospitalized coronavirus disease 2019-positive patients predicted for higher mortality and prolonged intensive care unit and hospital stays in a multisite healthcare system.
    Erben Y; Franco-Mesa C; Gloviczki P; Stone W; Quinones-Hinojoas A; Meltzer AJ; Lin M; Greenway MRF; Hamid O; Devcic Z; Toskich B; Ritchie C; Lamb CJ; De Martino RR; Siegel J; Farres H; Hakaim AG; Sanghavi DK; Li Y; Rivera C; Moreno-Franco P; O'Keefe NL; Gopal N; Marquez CP; Huang JF; Kalra M; Shields R; Prudencio M; Gendron T; McBane R; Park M; Hoyne JB; Petrucelli L; O'Horo JC; Meschia JF
    J Vasc Surg Venous Lymphat Disord; 2021 Nov; 9(6):1361-1370.e1. PubMed ID: 33836287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study.
    Martínez-Sanz J; Muriel A; Ron R; Herrera S; Pérez-Molina JA; Moreno S; Serrano-Villar S
    Clin Microbiol Infect; 2021 Feb; 27(2):238-243. PubMed ID: 32979572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19).
    Maslennikov R; Ivashkin V; Vasilieva E; Chipurik M; Semikova P; Semenets V; Russkova T; Levshina A; Grigoriadis D; Magomedov S; Efremova I; Dzhakhaya N
    Eur Cytokine Netw; 2021 Mar; 32(1):8-14. PubMed ID: 34346869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of tocilizumab therapy in severe or critical COVID-19 patients: A retrospective cohort, single-centre study.
    Abdelnaby H; Aboelhassan W; Al-Jarallah M; Rajan R; Dashti R; Zhanna KD; Alsaber AR; Abd El-Aleem A; Ashry I; Abdullah M; Mahmoud Fouad A
    Trop Med Int Health; 2021 Dec; 26(12):1689-1699. PubMed ID: 34601803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
    Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
    J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19 and IL-6: Why vitamin D (probably) helps but tocilizumab might not.
    Silberstein M
    Eur J Pharmacol; 2021 May; 899():174031. PubMed ID: 33722593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19.
    Guirao JJ; Cabrera CM; Jiménez N; Rincón L; Urra JM
    Mol Immunol; 2020 Dec; 128():64-68. PubMed ID: 33075636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between tocilizumab treatment of hyperinflammatory patients with COVID-19 in a critical care setting and elevated incidence of hospital-acquired bacterial and invasive fungal infections.
    Minihan B; McAuliffe E; Powell J; Wong SL; Wilkie K; Murphy C; Maher A; Power L; O'Connell NH; Dunne CP
    J Hosp Infect; 2022 Aug; 126():29-36. PubMed ID: 35472487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is Tocilizumab An Effective Therapy For Severe Covid-19: A Single Center Study.
    Sarfaraz S; Shaikh Q; Iftikhar S; Herekar FF; Saleem SG; Kanani F
    J Ayub Med Coll Abbottabad; 2022; 34(4):747-754. PubMed ID: 36566393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2.
    Saffo Z; Guo W; Springer K; Maksimowicz-McKinnon K; Kak V; McKinnon JE; Bhargava P
    J Osteopath Med; 2021 Jul; 121(8):705-714. PubMed ID: 34237804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients.
    Borku Uysal B; Ikitimur H; Yavuzer S; Ikitimur B; Uysal H; Islamoglu MS; Ozcan E; Aktepe E; Yavuzer H; Cengiz M
    J Med Virol; 2020 Nov; 92(11):2648-2656. PubMed ID: 32484930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management.
    Antony SJ; Davis MA; Davis MG; Almaghlouth NK; Guevara R; Omar F; Del Rey F; Hassan A; Arian MU; Antony N; Prakash BV
    J Med Virol; 2021 Jan; 93(1):491-498. PubMed ID: 32644254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
    Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
    Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis.
    Wei Q; Lin H; Wei RG; Chen N; He F; Zou DH; Wei JR
    Infect Dis Poverty; 2021 May; 10(1):71. PubMed ID: 34001244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Divergent impacts of tocilizumab and colchicine in COVID-19-associated coagulopathy: the role of alpha-defensins.
    Abdeen S; Abu-Fanne R; Bdeir K; Maraga E; Higazi M; Cines DB; Heyman SN; Higazi AA
    Br J Haematol; 2022 Feb; 196(4):923-927. PubMed ID: 34622440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.